Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shalini Hede

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of Medical Economics|July 27, 2017
Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United StatesCatherine Saint-Laurent Thibault, Divya Moorjaney, Michael L Ganz, et al.
Journal of Medical Economics|March 16, 2017
Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United StatesCatherine Saint-Laurent Thibault, Divya Moorjaney, Michael L Ganz, et al.
Current Medical Research and Opinion|September 26, 2017
Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillationShuqian Liu, Xiaoyan Li, Qian Shi, et al.
Journal of Managed Care & Specialty Pharmacy|September 14, 2018
Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense PopulationKiran Gupta, Jeffrey Trocio, Allison Keshishian, et al.
Eclinicalmedicine|February 19, 2025
R-index: a standardized representativeness metric for benchmarking diversity, equity, and inclusion in biopharmaceutical clinical trial developmentSpencer L James, Max Bourgognon, Patricia Pinto Vieira, et al.
Advances in Therapy|August 1, 2025
Five Data-Informed Principles for Advancing Inclusive Research in Clinical Trials: A Pharma PerspectiveSpencer L James, Shalini Hede, Altovise T Ewing-Crawford, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of Medical Economics|July 27, 2017
Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United StatesCatherine Saint-Laurent Thibault, Divya Moorjaney, Michael L Ganz, et al.
Journal of Medical Economics|March 16, 2017
Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United StatesCatherine Saint-Laurent Thibault, Divya Moorjaney, Michael L Ganz, et al.
Current Medical Research and Opinion|September 26, 2017
Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillationShuqian Liu, Xiaoyan Li, Qian Shi, et al.
Journal of Managed Care & Specialty Pharmacy|September 14, 2018
Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense PopulationKiran Gupta, Jeffrey Trocio, Allison Keshishian, et al.
Eclinicalmedicine|February 19, 2025
R-index: a standardized representativeness metric for benchmarking diversity, equity, and inclusion in biopharmaceutical clinical trial developmentSpencer L James, Max Bourgognon, Patricia Pinto Vieira, et al.
Advances in Therapy|August 1, 2025
Five Data-Informed Principles for Advancing Inclusive Research in Clinical Trials: A Pharma PerspectiveSpencer L James, Shalini Hede, Altovise T Ewing-Crawford, et al.
Pageof 1